Dvorak, Christopher C <br/><br/>
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.  [electronic resource] 

 -  Pediatric blood & cancer  07 2018 
 - e27034 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.27034  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Busulfan--administration & dosage<br/>Child<br/>Child, Preschool<br/>Female<br/>Follow-Up Studies<br/>Graft Rejection--drug therapy<br/>Graft vs Host Disease--drug therapy<br/>Hematopoietic Stem Cell Transplantation--adverse effects<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Leukemia, Myelomonocytic, Juvenile--complications<br/>Male<br/>Myeloablative Agonists--administration & dosage<br/>Prognosis<br/>Transplantation Conditioning<br/>Vidarabine--administration & dosage